A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Mesothelioma, Malignant
BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin
Overall Survival (OS), Up to 58 months
Objective Response Rate (ORR) by modified Response Evaluation Criteria in Solid Tumors (m-RECIST) by Investigator, Up to 58 months|Progression Free Survival (PFS) by m-RECIST by Investigator, Up to 58 months|Incidence of Adverse Events (AEs), Up to 58 months|Incidence of Serious Adverse Events (SAEs), Up to 58 months|Incidence of immune-related AEs, Up to 58 months|Incidence of deaths, Up to 58 months|Incidence of participants with laboratory abnormalities, Up to 58 months
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.